Cargando…
Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE(®)) in the management of hemophilia A
Removal of blood-based additives from recombinant clotting factor concentrates continues to be advocated by the hemophilia community due to the history of infectious disease transmission with previous blood-derived clotting factor concentrates. In 2003, octocog-alpha, antihemophilic factor (recombin...
Autor principal: | Shapiro, Amy D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291300/ https://www.ncbi.nlm.nih.gov/pubmed/18078007 |
Ejemplares similares
-
Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies
por: Sottilotta, Gianluca, et al.
Publicado: (2017) -
Final Results of the Prospective ADVATE(®) Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII
por: Shapiro, Amy D, et al.
Publicado: (2021) -
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009) -
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023) -
Octocog alfa: Lack of efficacy: case report
Publicado: (2022)